Introduction
============

Thyroid cancer is one of the most common malignancies in the world with an estimated 53,990 new cases and 2,060 mortalities expected in the USA in 2018 ([@b1-ijo-53-05-1927]). Thyroid carcinoma is considered a well-differentiated type of thyroid cancer and accounts for \~80% of all types of thyroid cancer ([@b2-ijo-53-05-1927]). Although patients with thyroid carcinoma tend to have a good prognosis, a number of patients die from cancer metastasis and proliferation in a short time ([@b3-ijo-53-05-1927]). With the development of medical and technical tools, numerous studies on thyroid carcinoma have been published in the past decades ([@b4-ijo-53-05-1927]-[@b6-ijo-53-05-1927]). However, the underlying mechanisms of thyroid carcinoma remain unclear.

With the progress made in whole genome sequencing technologies, long non-coding RNAs (lncRNAs) have attracted increasing attention from the scientific community ([@b7-ijo-53-05-1927]-[@b9-ijo-53-05-1927]). lncRNAs are a group of RNAs \>200 nucleotides in length that have lost the ability to encode proteins ([@b10-ijo-53-05-1927]). Accumulating evidence indicates that dysregulation of lncRNAs has a major role in the physiological progression of carcinogenesis. Gou *et al* ([@b11-ijo-53-05-1927]) reported that high expression of lncRNA PVT1 promotes hepatocellular carcinoma progression by influencing microRNA (miR)-214. lncRNA SPRY4 intronic transcript 1 (SPRY4-IT1) has a lower expression level in lung adenocarcinomas than in normal tissue, and dysregulation of lncRNA SPRY4-IT1 alters the invasion and migration abilities of cancer cells ([@b12-ijo-53-05-1927]). In addition, a series of reports have indicated that lncRNAs have crucial roles in the pathogenesis of thyroid cancer ([@b13-ijo-53-05-1927]-[@b15-ijo-53-05-1927]). However, the association between thyroid carcinoma and lncRNAs requires further study.

As a newly discovered lncRNA encoded by chromosome 17q25.1, long intergenic non-protein coding RNA 673 (LINC00673) lacks the ability to encode a protein. Lu *et al* ([@b16-ijo-53-05-1927]) reported that LINC00673 is upregulated in non-small cell lung cancer, and that it sponges miR-150-5p and modulates ZEB1 indirectly. Additionally, LINC00673 may be a prognostic indicator of overall survival in breast cancer ([@b17-ijo-53-05-1927]). Yu *et al* ([@b18-ijo-53-05-1927]) demonstrated that overexpression of LINC00673 is associated with poor prognosis, and promotes invasion and metastasis in tongue squamous cell carcinoma. Unfortunately, there are no studies that describe the role of LINC00673 in thyroid cancer.

In a previous unpublished study, whole-transcriptome resequencing of 19 paired thyroid carcinoma tissue samples was performed and revealed that LINC00673 was upregulated in the tumor tissues compared with non-tumor tissues. In this study, 58 matched pairs of thyroid carcinoma and adjacent normal tissues were examined to further validate the dysregulation of LINC00673. The function of LINC00673 in thyroid carcinoma cell lines was also investigated. This study aimed to determine the role of LINC00673 in thyroid carcinoma.

Materials and methods
=====================

Patients and thyroid tissue samples
-----------------------------------

This study examined 60 matched pairs of thyroid carcinoma and adjacent non-tumor tissue samples (age range, 27-81 years; male/female, 3:2) resected in the Department of Thyroid and Breast Surgery at The First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China) between February 2016 and July 2017. Fresh thyroid carcinoma tissues and non-tumor tissues were snap-frozen in liquid nitrogen. All patient-derived information was recorded following the protocols approved by the ethical standards of the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. Written informed consent was obtained from each individual participant. The Kruppel-like factor 2 (KLF2) reads per kilobases per million reads expression value was obtained from The Cancer Genome Atlas (TCGA) portal. Sequence data from 502 thyroid carcinomas complete clinical features and 57 normal thyroid tissues was selected.

Cell culture and growth conditions
----------------------------------

TPC1, KTC-1, BCPAP and HTORI-3 were received from Professor Mingzhao Xing of Johns Hopkins University School of Medicine (Baltimore, MA, USA). The TPC1, KTC-1 and BCPAP cell lines were cultured in RPMI-1640 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.), 100 mg/ml streptomycin and double-antibiotic 100 U/ml penicillin (Invitrogen; Thermo Fisher Scientific, Inc.). All thyroid cancer cell lines were incubated under an atmosphere of air containing 5% CO~2~ at 37°C.

Cell transfection
-----------------

Thyroid cell line transfection was conducted using small interfering RNA (siRNA) and Lipofectamine^®^ RNAiMAX transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. Cells were plated in a 6-well plate 24 h before transfection. TPC1 (8×10^4^), BCPAP or KTC-1 (2×10^5^) cells were transfected using 10 *µ*l (TPC1), 7.5 *µ*l (KTC-1) or 5 *µ*l (BCPAP) siRNA (20 *µ*M) and 4 *µ*l RNAiMAX (Thermo Fisher Scientific, Inc.) in a 6-well plate according to the manufacturer's recommendations. The siRNA sequences used in the study were as follows: LINC00673 siRNA-1, forward 5′-GCCUUUGUACUCAGCAAUUTT-3′ and reverse 5′-AAUUGCUGAGUACAAAGGCTT-3′; LINC00673 siRNA-2, forward 5′-GGAUACAGAGU GAAUAGUUTT-3′ and reverse 5′-AACUAUUCACUCUGUAUCCTT-3′; KLF-2 siRNA, forward 5′-GGGCCUUAAUUUGUACUGUTT-3′ and reverse 5′-ACAGUACAAAUUAAGGCCCTT-3′. si-NC, forward 5′-UUCUCCGAACGUGUCACGUTT-3′ reverse 5′-ACGUGACACGUUCGGAGAATT-3′. All siRNAs were provided by Shanghai GenePharma Co., Ltd. (Shanghai, China).

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
-----------------------------------------------------------------------------------------

The total RNA from tissues and cells was isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The total RNA samples were reverse transcribed by the ReverTra Ace qPCR RT Kit (Toyobo Life Science, Osaka, Japan) according to the manufacturer's protocol. qPCR reactions were performed using a real-time PCR system (Applied Biosystems 7500; Applied Biosystems; Thermo Fisher Scientific, Inc.) using the Thunderbird SYBR qPCR Mix (Toyobo Life Science). The primer sequences used were as follows: LINC00673, forward 5′-TGCTGATGACACATACACA-3′ and reverse 5′-GACAAGGATGAACCATGATAG-3′; KLF-2, forward 5′-CTGCACATGAAACGGCACAT-3′ and reverse 5′-CAGTCACAGTTTGGGAGGGG-3′; GADPH, forward 5′-GTCTCCTCTGACTTCAACAGCG-3′ and reverse 5′-ACCACCCTGTTGCTGTAGCCAA-3′.

The relative expression of genes was normalized to GADPH expression and calculated according to the 2^−ΔΔCq^ method described by Livak and Schmittgen ([@b19-ijo-53-05-1927]).

Invasion and migration assays
-----------------------------

In Transwell assays, KTC-1 (5×10^4^ cells) and BCPAP (5×10^4^ cells) were seeded in the upper chamber with 10% fetal bovine serum and 600 *µ*l medium containing 20% FBS was added to the lower chamber. After 20-24 h, the membranes were fixed with 4% paraformaldehyde for 30 min and stained with 0.4% crystal violet solution for 30 min at 37°C. Cell migration and invasion abilities were evaluated by counting the cells. Five random fields of view were selected to count the cell numbers, and images were captured under a light microscope at a magnification of ×20.

Cell proliferation assays
-------------------------

In the colony formation assay, TPC1 cells (2×10^3^ cells), KTC-1 cells (3×10^3^ cells) and BCPAP cells (3×10^3^ cells) were plated in 6-well plates. The cells were maintained in RPMI-1640 with 10% FBS for 7 days and then fixed with 4% paraformaldehyde for 30 min and stained with 0.4% crystal violet solution for 30 min at 37°C. Images were captured using a camera.

In the CCK-8 assay, TPC1 cells (2×10^3^ cells), KTC-1 cells (3×10^3^ cells) and BCPAP cells (3×10^3^ cells) were plated in 96-well plates for 24 h and then transfected with siRNA. The cells were incubated for 24, 48, 72 or 96 h. All experiments were performed in triplicate.

Western blot analysis
---------------------

Protein extraction buffers (radioimmunoprecipitation assay and phenylmethane sulfonyl fluoride; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) were added to the cells, and the protein concentrations were quantified using a bicinchoninic acid (BCA) kit. The samples were then homogenized, centrifuged at 12,000 × g at 4°C for 30 min, then subjected to ultra-sonication (each action 5 sec, intermittent 6 sec and each specimen 5 times). The supernatant was removed via centrifugation at 4,000 × g at 4°C for 20 min. The sample was used to perform quantification of the protein expression with BCA. According to the manufacturer's protocol, 20 *µ*g from each sample were separated by 10% SDS-polyacrylamide gel electrophoresis (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and then transferred to PVDF membranes (EMD Millipore, Billerica, MA, USA). PVDF membranes were then incubated with blocking buffer (PBS with 5% non-fat milk and 0.1% Tween-20) for 1 h at room temperature. Membranes were subsequently washed three times with Tris-buffered saline/Tween-20 for 5 min each and incubated overnight with primary antibodies at 4°C.

The primary antibodies used in this study were as follows: N-cadherin (cat no. 13116; 1:1,000 dilution; Cell Signaling Technology, Inc., Danvers, MA, USA), vimentin (cat. no. 5741; 1:1,000 dilution; Cell Signaling Technology, Inc.), E-cadherin (cat. no. 3195; 1:1,000 dilution; Cell Signaling Technology, Inc.), KLF-2 (cat. no. ab203591; 1:500 dilution; Abcam, Cambridge, MA, USA), and human β-actin (cat no. 3700; 1:1,000 dilution; Cell Signaling Technology, Inc.). Anti-rabbit IgG (cat. no. 7074; 1:3,000 dilution; Cell Signaling Technology, Inc.) and anti- mouse IgG (cat. no. 7076; 1:3,000 dilution; Cell Signaling Technology, Inc.) horseradish peroxidase-conjugated secondary antibodies were used for 2 h at room temperature. The enhanced chemiluminescence kit (Beyotime Institute of Biotechnology) was used to detect results of western blot analysis. The relative level of each protein was deduced from the ratio of the mean value of each band to that of β-actin. The relative densities were quantified with a digital imaging analyzer, ImageJ 1.4.1 (National Institutes of Health, Bethesda, MA, USA).

Statistical analysis
--------------------

All of the statistical analyses were performed using SPSS 23.0 software (IBM Corp., Armonk, NY, USA). Disease-free survival rates were evaluated using Kaplan-Meier curves, and the Cox proportional hazards regression model was used to evaluate the hazard ratio (HR). Log-rank test is used to compare two or more groups by testing the null hypothesis. The null hypothesis states that the populations do not differ in the probability of an event at any time-point. Thus, log-rank test is the most commonly-used statistical test to compare the survival functions of two or more groups. Kaplan Meier and Cox regression analyses were used to assess the association between LINC00673 and overall survival, and prognosis. Data are presented as the mean ± standard deviation. The differences in characteristics between two groups were examined by the Student's t-test. The differences in characteristics between three groups were examined by analysis of variance, and the least significant difference test was applied to detect the differences between each pair of groups. The expression difference between two groups from TCGA database was used by Mann-Whitney U test. Clinicopathological characteristics were evaluated using the χ^2^ test. Pearson correlation analysis was used to evaluate correlation between LINC00673 and KLF-2 expression in validate cohort. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Upregulation of LINC00673 in thyroid carcinoma tissues and the associated between LINC00673 expression and clinical features
----------------------------------------------------------------------------------------------------------------------------

To validate the RNA sequencing results (unpublished data), the expression levels of LINC00673 in 60 matched pairs of thyroid carcinoma and adjacent non-tumor tissues, 1 normal thyroid cell line and 3 thyroid carcinoma cell lines were examined using RT-qPCR. The results indicated that LINC00673 expression was higher in tumor tissues than in adjacent normal tissues (P\<0.05; [Fig. 1A](#f1-ijo-53-05-1927){ref-type="fig"}). To further understand the association between LINC00673 and thyroid carcinoma, the patients were divided into low-expression and high-expression groups according to the median value in the validation cohort. As shown in [Table I](#tI-ijo-53-05-1927){ref-type="table"}, tumor size (P=0.015) and lymph node metastasis (P=0.01) were significantly associated with LINC00673 expression. These results indicate that LINC00673 is upregulated in thyroid carcinoma and that it may function as an oncogene.

LINC00673 regulates the proliferation of thyroid carcinoma cell lines
---------------------------------------------------------------------

As demonstrated in [Fig. 1B](#f1-ijo-53-05-1927){ref-type="fig"}, LINC00673 expression in the TPC1 cell line was significantly higher than that of the normal thyroid cell line HTORI-3, while the KTC-1 and BCPAP cells lines exhibited relatively low LINC00673 expression (P\<0.05; [Fig. 1B](#f1-ijo-53-05-1927){ref-type="fig"}). Subsequently, loss-of-function and gain-of-function experiments were performed to determine the role of LINC00673 in thyroid carcinoma. LINC00673 expression was knocked down in TPC1 cells using siRNA, and LINC00673 was overexpressed in KTC-1 and BCPAP cells using a pcDNA vector ([Fig. 1C and D](#f1-ijo-53-05-1927){ref-type="fig"}). The CCK-8 assay and colony formation experiments were performed to assess the effects of LINC00673 on thyroid carcinoma cell proliferation. As demonstrated in [Fig. 2A-C](#f2-ijo-53-05-1927){ref-type="fig"}, thyroid carcinoma cell proliferation was significantly inhibited in TPC1 cells by knocking down LINC00673 expression (transfected with siRNA-1 or siRNA-2) compared with the control cells (transfected with si-NC); whereas, upregulation of LINC00673 enhanced KTC-1 and BCPAP cell proliferation compared with the vector control. Cell colony formation was also significantly inhibited in TPC1 cells by knocking down LINC00673 expression compared with control cells; whereas overexpression of LINC00673 exhibited the opposite effect in KTC-1 and BCPAP cells ([Fig. 2D-F](#f2-ijo-53-05-1927){ref-type="fig"}).

LINC00673 regulates the metastasis of thyroid carcinoma cell lines by modulating epithelial-mesenchymal transition (EMT)
------------------------------------------------------------------------------------------------------------------------

Given the association between LINC00673 expression and clinicopathological features, the role of LINC00673 in the migration and invasion of TPC cell lines was investigated. The results showed that downregulated LINC00673 weakened migration and invasion of TPC1 cells compared with control cells ([Fig. 3A and B](#f3-ijo-53-05-1927){ref-type="fig"}); whereas overexpression of LINC00673 had the opposite effect in KTC-1 and BCPAP cells ([Fig. 3C and D](#f3-ijo-53-05-1927){ref-type="fig"}). Previous studies have demonstrated that EMT is a key process during metastasis ([@b20-ijo-53-05-1927],[@b21-ijo-53-05-1927]). Thus, the protein levels of epithelial and mesenchymal markers were examined in thyroid carcinoma cell lines. As demonstrated in [Fig. 4](#f4-ijo-53-05-1927){ref-type="fig"}, knocking down LINC00673 reduced the expression of N-cadherin and vimentin, and enhanced E-cadherin expression; whereas, overexpression of LINC00673 had the opposite effect, suggesting that LINC00673 may regulate metastasis by altering EMT.

KLF-2 is a potential downstream target of LINC00673
---------------------------------------------------

Huang *et al* ([@b22-ijo-53-05-1927]) reported that the oncogenic function of LINC00673 is partially dependent on repression of KLF2. In this study, knock down of LINC00673 enhanced the protein levels of KLF-2, while upregulation of LINC00673 inhibits the expression of KLF-2 ([Fig. 5A](#f5-ijo-53-05-1927){ref-type="fig"}). Additionally, KLF2 mRNA expression was assessed in 58 matched pairs of thyroid carcinoma tumor samples and adjacent normal tissues by RT-qPCR, which demonstrated that KLF-2 has lower expression in thyroid carcinoma tumor samples than that in normal samples ([Fig. 5B](#f5-ijo-53-05-1927){ref-type="fig"}). The same trend was also observed in a TCGA cohort ([Fig. 5C](#f5-ijo-53-05-1927){ref-type="fig"}). Pearson correlation analysis indicated a negative correlation between LINC00673 and KLF-2 expression in 50 paired clinical thyroid carcinoma tissues ([Fig. 5D](#f5-ijo-53-05-1927){ref-type="fig"}). These results suggest that KLF-2 is a potential downstream target of LINC00673.

Association between KLF-2 expression and patient clinicopathologic features
---------------------------------------------------------------------------

To determine whether KLF-2 expression is involved in thyroid carcinoma tumorigenesis, the association between KLF-2 and patient clinical features was evaluated. The validated cohort was divided into a high-expression group and a low-expression group according to KLF-2 median expression level. As presented in [Table II](#tII-ijo-53-05-1927){ref-type="table"}, patients with a lower expression level of KLF-2 had a larger tumor size than in the high expression group (P=0.002). In the TCGA cohort ([Table III](#tIII-ijo-53-05-1927){ref-type="table"}), the results revealed that low KLF-2 expression was associated with tumor size (P\<0.001), lymph node metastasis (P=0.007), histological type (P=0.001) and T stage (P\<0.001). As presented in [Fig. 6](#f6-ijo-53-05-1927){ref-type="fig"}, the difference between the survival curves of the two groups was statistically significant (P=0.0011). This finding indicated that low KLF-2 expression was associated with an unfavorable prognosis in patients with thyroid carcinoma.

Restoration of KLF-2 induces thyroid carcinoma cell proliferation and metastasis
--------------------------------------------------------------------------------

As shown in [Fig. 7A](#f7-ijo-53-05-1927){ref-type="fig"}, KLF-2 expression in the TPC1, KTC-1 and BCPAP cell lines was significantly lower than that of the HTORI-3 cell line. To further confirm whether KLF-2 influences the progression of thyroid carcinoma, KLF-2 expression was knocked down in the TPC1, KTC-1 and BCPAP cell lines using siRNA and confirmed the knockdown efficiency at the RNA and protein levels ([Fig. 7B and C](#f7-ijo-53-05-1927){ref-type="fig"}). The results from the validated and TCGA cohorts suggest that the expression of KLF-2 is associated with tumor size; thus, we hypothesized that abnormal expression of KLF-2 may influence the proliferation of thyroid carcinoma cells. The CCK-8 and colony formation assays were performed, and the results demonstrated that knockdown of KLF-2 enhanced the proliferation of TPC1, KTC-1 and BCPAP cell lines ([Fig. 7D and E](#f7-ijo-53-05-1927){ref-type="fig"}). Transwell migration and invasion assays were then performed to examine the metastatic ability of the thyroid carcinoma cell lines. As presented in [Fig. 8A](#f8-ijo-53-05-1927){ref-type="fig"}, the number of migrating cells was significantly increased by knocking down KLF-2 expression in the cell lines. Consistent with previous findings, the invasion ability was induced in thyroid carcinoma cell lines by knocking down KLF-2 expression compared with the control group ([Fig. 8B](#f8-ijo-53-05-1927){ref-type="fig"}).

Oncogenic role of LINC00673 is partly dependent on repressing KLF-2 expression
------------------------------------------------------------------------------

To determine whether KLF-2 influences the LINC00673-associated enhancement of proliferation and metastasis in thyroid carcinoma cells, rescue experiments were performed. TPC1 and BCPAP cells were co-transfected with LINC00673 and KLF2 siRNAs. CCK-8 assay and Transwell assays demonstrated that knocking down KLF2 partially rescued the LINC00673 silencing-mediated effects on cell growth and invasion/metastasis in TPC1 and BCPAP cells ([Fig. 9](#f9-ijo-53-05-1927){ref-type="fig"}). As demonstrated in [Fig. 10](#f10-ijo-53-05-1927){ref-type="fig"}, co-transfection with LINC00673 and KLF2 siRNA partially rescued the effects of LINC00673 downregulation on KLF-2 and E-cadherin upregulation, and the downregulation mesenchymal markers, N-cadherin and vimentin, was also partially rescued. These results suggest that KLF-2 is an important mediator of LINC00673-associated cell proliferation, metastasis and EMT.

Discussion
==========

Thyroid cancer is one of the fastest growing malignancies worldwide with a rate of 4% per year ([@b23-ijo-53-05-1927]). Despite extensive research on lncRNAs and thyroid carcinoma ([@b24-ijo-53-05-1927]-[@b26-ijo-53-05-1927]), the underlying molecular mechanisms responsible for the function of lncRNAs in thyroid carcinoma are not well understood.

In a previously unpublished study, we selected 19 matched pairs of thyroid carcinoma tumor tissues and adjacent non-cancer tissues to conduct whole transcriptome resequencing, and the results revealed that LINC00673 expression was higher in tumor tissues than in adjacent normal thyroid tissues. Ma *et al* ([@b27-ijo-53-05-1927]) reported that LINC00673 binds to histone-lysine N-methyltransferase EZH2 and silences homeobox protein HOXA5 to promote non-small cell lung cancer metastasis. However, the association between LINC00673 and tumorigenesis remains unclear. The findings in this study demonstrated that LINC00673 expression is higher in thyroid tumor tissues and that patients with higher LINC00673 have larger tumors and increased lymph node metastasis compared with normal tissues. Loss-of-function and gain-of-function experiments were performed to demonstrate the function of LINC00673 in cell proliferation and metastasis. The findings also indicated that knocking down LINC00673 may enhance the protein level of E-cadherin, and inhibit expression of N-cadherin and vimentin, while upregulation of LINC00673 had the opposite effect. In addition, knock down of LINC00673 enhanced the protein levels of KLF-2, and upregulation of LINC00673 inhibited KLF-2 expression.

KLF-2 is located at chromosome 19p13.11 and is \~2,800 bp in length. Although previous studies have reported that KLF-2 is dysregulated in cancer and has an influence on tumorigenesis in various cancer tissues ([@b28-ijo-53-05-1927]-[@b30-ijo-53-05-1927]), very little is known about its biological role and the mechanism of action of KLF-2 in thyroid carcinoma. In the current study, it was demonstrated that the expression of KLF-2 is lower in thyroid tumor tissues than that in normal tissues, in a validated cohort and in a TCGA cohort. The expression of KLF-2 was negatively correlated with the expression of LINC00673 in the validated cohort, and lower KLF-2 expression was associated with increased lymph node metastasis and a larger tumor size. KLF-2 downregulation markedly enhanced the proliferation and metastasis of thyroid cancer cells. Knocking down KLF2 partially rescued the effects of LINC00673 silencing and resulted in increased thyroid carcinoma cell growth and metastasis. These results suggest that LINC00673 functions as an oncogene in thyroid carcinoma, partially by inhibiting KLF-2 expression.

Despite these findings, some limitations do exist. The number of patients included in the validated cohort should be increased to provide more convincing results. Additionally, *in vivo* experiments should be conducted to validate the oncogenic effects of LINC00673.

In summary, LINC00673 is upregulated in thyroid carcinoma, and the abnormal expression may exert an oncogenic functional role in thyroid carcinoma. The findings of this study provide a potential new marker and target for gene therapy in thyroid carcinoma.
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![Expression of LINC00673 in a thyroid carcinoma cohort and in thyroid carcinoma cell lines. (A) LINC00673 expression was detected by RT-qPCR in 58 matched pairs of thyroid carcinoma and adjacent non-tumor tissues (paired t-test, ^\*^P\<0.05). (B) Relative expression of LINC00673 (normalized to the GAPDH gene) was examined via RT-qPCR. Compared with normal thyroid cell lines, the TPC1 cell line had higher LINC00673 expression, while the KTC-1 and BCPAP cell lines had lower expression. (C) The relative expression of LINC00673 (compared with the GAPDH gene) in the TPC1 cell line. Compared to the control group, the expression of LINC00673 was lower in the SiRNA group. (D) The relative expression of LINC00673 (compared with the GAPDH gene) in KTC-1 and BCPAP cell lines. Compared with the control group, the expression of LINC00673 in the LINC00673 group was higher. ^\*^P\<0.05, ^\*\*^P\<0.01, ^\*\*\*^P\<0.001 vs. treated with si-NC or a vector control using one-way analysis of variance. RT-qPCR, reverse transcription-quantitative polymerase chain reaction.](IJO-53-05-1927-g00){#f1-ijo-53-05-1927}

![Dysregulation of LINC00673 gene expression in thyroid carcinoma cells inhibits proliferation and cell colony formation. TPC1 cells transfected with siRNA or si-NC were cultured in 96-well plates for 1-4 days, and then the CCK-8 assay was used to measure cell proliferation. Cell proliferation was significantly suppressed in thyroid carcinoma cells transfected with siRNA. (B) KTC-1 and (C) BCPAP cell lines transfected with LINC00673 or a vector control were cultured in 96-well plates for 1-4 days, and then the CCK-8 assay was used to measure cell proliferation. Cell proliferation was significantly enhanced in thyroid carcinoma cells transfected with LINC00673. (D) TPC1 cells transfected with siRNA or si-NC were cultured in 6-well plates for 10-14 days. (E) KTC-1 and (F) BCPAP cell lines transfected with LINC00673 or a vector control were cultured in 6-well plates for 10-14 days. ^\*^P\<0.05, ^\*\*^P\<0.01 vs. si-NC or a vector control using one-way analysis of variance. LINC00673, long intergenic non-protein coding RNA 673; si-NC, siRNA negative control; siRNA, small interfering RNA.](IJO-53-05-1927-g01){#f2-ijo-53-05-1927}

![Dysregulation of LINC00673 gene expression in thyroid carcinoma cells inhibits migration and invasion. (A) In TPC1 cells, Transwell migration assays in LINC00673 knockdown cells and the corresponding control cells. (B) In TPC1 cells, Transwell invasion assays in LINC00673 knockdown cells and the corresponding control cells. (C) In KTC and BCPAP cells, Transwell migration assays in LINC00673 overexpression cells and the corresponding control cells. (D) In KTC and BCPAP cells, Transwell invasion assays in LINC00673 overexpression cells and the corresponding control cells. The columns represent the mean number of migrating or invading cells from at least three independent experiments. ^\*^P\<0.05, ^\*\*^P\<0.01 vs. si-NC or vector using one-way analysis of variance. si-NC, siRNA negative control; siRNA, small interfering RNA; LINC00673, long intergenic non-protein coding RNA 673.](IJO-53-05-1927-g02){#f3-ijo-53-05-1927}

![Effect of LINC00673 on epithelial-mesenchymal transition proteins in thyroid carcinoma cell lines (TPC1, KTC-1 and BCPAP). E-cadherin N-cadherin, and vimentin protein expression determined by western blotting in TPC1 cells transfected with siRNA or si-NC, and KTC-1 and BCPAP cells transfected with empty vector or LINC00673 overexpression vector. si-NC, siRNA negative control; siRNA, small interfering RNA; LINC00673, long intergenic non-protein coding RNA 673.](IJO-53-05-1927-g03){#f4-ijo-53-05-1927}

![The expression of KLF-2 in a validated cohort of patients with thyroid carcinoma and in thyroid carcinoma cell lines. (A) Western blot analysis of the KLF-2 protein level after downregulation (siRNA) or upregulation of LINC00673. (B) KLF-2 expression was detected by RT-qPCR in 58 matched pairs of thyroid carcinoma and adjacent non-tumor tissues. (C) The Cancer Genome Atlas cohort contained 502 thyroid tumor tissues and 57 normal tissues. Reads per kilobase per million is used as the level of KLF-2. The data were analyzed using the Mann-Whitney U test. (D) Analysis of the relationship between LINC00673 expression (ΔCq value) and KLF-2 mRNA level (ΔCq value) in 45 thyroid carcinoma tissues. ^\*\*\*^P\<0.001. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; KLF-2, Kruppel-like factor 2; si-NC, small interfering RNA negative control; siRNA, small interfering RNA; LINC00673, long intergenic non-protein coding RNA 673.](IJO-53-05-1927-g04){#f5-ijo-53-05-1927}

![Kaplan-Meier analysis of disease-free survival of patients with thyroid carcinoma in the Cancer Genome Atlas cohort with different levels of KLF-2 expression. Patients with lower KLF-2 expression had a shorter disease-free survival time compared with patients with higher KLF-2 expression. KLF-2, Kruppel-like factor 2; HR, hazard ratio; TPM, transcripts per million.](IJO-53-05-1927-g05){#f6-ijo-53-05-1927}

![Downregulation of KLF-2 enhances thyroid carcinoma cell line proliferation and cell colony formation. (A) The relative expression of KLF-2 (compared with the GAPDH gene) was examined via RT-qPCR in a normal thyroid cell line (HTORI-3), and thyroid carcinoma cell lines (TPC1, KTC-1 and BCPAP). (B) RT-qPCR analysis and (C) western blot analysis of KLF-2 mRNA and protein levels in si-NC and si-KLF2 transfected cells. (D) Cell proliferation assay: TPC1, KTC-1 and BCPAP cell lines transfected with si-KLF2 or si-NC were cultured in 96-well plates for 1-4 days, and then cell proliferation was measured using the CCK-8 assay. Cell proliferation was significantly enhanced in TPC1, KTC-1 and BCPAP cells transfected with si-KLF2. (E) TPC1, KTC-1 and BCPAP cell lines transfected with si-KLF2 or si-NC were cultured in 6-well plates for 10-14 days. ^\*^P\<0.05 vs. si-NC; comparison to cells treated with si-NC using Student's t-test. KLF-2, Kruppel-like factor 2; si, small interfering RNA; NC, negative control; OD, optical density.](IJO-53-05-1927-g06){#f7-ijo-53-05-1927}

![Downregulation of KLF-2 enhances the migration and invasion of thyroid carcinoma cell lines. (A) The number of migrating cells was higher in TPC1, KTC-1 and BCPAP cell lines transfected with si-KLF2 than in cells transfected with si-NC. (B) The number of invading cells was higher in TPC1, KTC-1 and BCPAP cell lines transfected with si-KLF2 than in cells transfected with si-NC. ^\*^P\<0.05, ^\*\*^P\<0.01 vs. si-NC using Student's t-test. si, small interfering RNA; NC, negative control; KLF-2, Kruppel-like factor 2.](IJO-53-05-1927-g07){#f8-ijo-53-05-1927}

![The oncogenic role of LINC00673 is partially dependent on repressing KLF-2 expression. (A) CCK-8 assays were performed to determine the viability of TPC1 and BCPAP cells transfected with si-NC, si-LINC00673 or si-LINC00673+si-KLF2. (B) Transwell migration assays were performed to determine the viability of TPC1 and BCPAP cells transfected with si-NC, si-LINC00673 or si-LINC00673+si-KLF2. (C) Transwell invasion assays were performed to determine the viability of TPC1 and BCPAP cells transfected with si-NC, si-LINC00673 or si-LINC00673+si-KLF2. ^\*^P\<0.05, ^\*\*^P\<0.01, ^\*\*\*^P\<0.001. si, small interfering RNA; NC, negative control; LINC00673, long intergenic non-protein coding RNA 673; KLF-2, Kruppel-like factor 2.](IJO-53-05-1927-g08){#f9-ijo-53-05-1927}

![Ability of LINC00673 to influence epithelial-mesenchymal transition is partially dependent on the repression of KLF-2 expression. Western blot analysis was performed to determine the protein levels of KLF-2, E-cadherin, N-cadherin and vimentin in cells transfected with si-NC, si-LINC00673 or si-LINC00673+si-KLF2. si, small interfering RNA; NC, negative control; LINC00673, long intergenic non-protein coding RNA 673; KLF-2, Kruppel-like factor 2.](IJO-53-05-1927-g09){#f10-ijo-53-05-1927}

###### 

Association between LINC00673 and clinicopathologic characteristics in the validated cohort.

  Clinicopathologic characteristics       Low expression (%)          High expression (%)         χ^2^    P-value
  --------------------------------------- --------------------------- --------------------------- ------- -----------------------------------------------------
  Age                                                                                             1.086   0.297
   ≤45                                    15 (50)                     11 (36.7)                           
   \>45                                   15 (50)                     19 (63.3)                           
  Sex                                                                                             2.5     0.114
   Female                                 15 (50)                     21 (70)                             
   Male                                   15 (50)                     9 ([@b30-ijo-53-05-1927])           
  Tumor size                                                                                      5.934   0.015[a](#tfn1-ijo-53-05-1927){ref-type="table-fn"}
   ≤10 mm                                 15 (50)                     6 ([@b20-ijo-53-05-1927])           
   \>10 mm                                15 (50)                     24 (80)                             
  Unilateral or bilateral                                                                         0.069   0.793
   Unilateral                             18 (60)                     17 (56.7)                           
   Bilateral                              12 (40)                     13 (43.3)                           
  Extrathyroidal invasion                                                                         1.118   0.29
   Yes                                    3 ([@b10-ijo-53-05-1927])   1 (3.3)                             
   No                                     27 (90)                     29 (96.7)                           
  Lymph node metastasis                                                                           6.696   0.01[a](#tfn1-ijo-53-05-1927){ref-type="table-fn"}
   Yes                                    11 (36.7)                   21 (70)                             
   No                                     19 (63.3)                   9 ([@b30-ijo-53-05-1927])           
  American Joint Cancer Committee stage                                                           0.287   0.592
   I+II                                   20 (66.7)                   18 (60)                             
   III+IV                                 10 (33.3)                   12 (40)                             

P\<0.05. n=60.

###### 

Association between KLF-2 and clinicopathologic characteristics in the validated cohort.

  Clinicopathologic characteristics       Low expression (%)   High expression (%)   χ^2^    P-value
  --------------------------------------- -------------------- --------------------- ------- -----------------------------------------------------
  Age                                                                                1.086   0.297
   ≤45                                    11 (36.7)            15 (50)                       
   \>45                                   19 (63.7)            15 (50)                       
  Sex                                                                                0       1
   Female                                 18 (60)              18 (60)                       
   Male                                   12 (40)              12 (40)                       
  Tumor size                                                                         9.32    0.002[a](#tfn2-ijo-53-05-1927){ref-type="table-fn"}
   ≤10 mm                                 4 (13.3)             15 (50)                       
   \>10 mm                                26 (86.7)            15 (50)                       
  Unilateral or bilateral                                                            1.714   0.19
   Unilateral                             15 (50)              20 (66.7)                     
   Bilateral                              15 (50)              10 (33.3)                     
  Extrathyroidal invasion                                                            0       1
   Yes                                    2 (6.7)              2 (6.7)                       
   No                                     28 (93.3)            28 (93.3)                     
  Lymph node metastasis                                                              2.411   0.121
   Yes                                    19 (63.3)            13 (43.3)                     
   No                                     11 (36.7)            17 (56.7)                     
  American Joint Cancer Committee stage                                              0.287   0.592
  I+II                                    18 (60)              20 (66.7)                     
  III+IV                                  12 (40)              10 (33.3)                     

P\<0.05. n=60.

###### 

Association between KLF-2 and clinicopathologic characteristics in The Cancer Genome Atlas cohort.

  Clinicopathologic characteristics       Low expression (%)   High expression (%)   χ^2^     P-value
  --------------------------------------- -------------------- --------------------- -------- -----------------------------------------------------
  Age                                                                                0        1
   ≤45                                    115                  115                            
   \>45                                   130                  130                            
  Sex                                                                                0.263    0.608
   Female                                 178                  183                            
   Male                                   67                   62                             
  Histological type                                                                  16.803   0.001[a](#tfn3-ijo-53-05-1927){ref-type="table-fn"}
   Classical                              184                  164                            
   Follicular                             33                   66                             
   Tall cell                              23                   11                             
   Other                                  5                    4                              
  Tumor size                                                                         13.871   0.000[a](#tfn3-ijo-53-05-1927){ref-type="table-fn"}
   ≤20 mm                                 50                   87                             
   \>20 mm                                195                  158                            
  T stage                                                                            13.871   0.000[a](#tfn3-ijo-53-05-1927){ref-type="table-fn"}
   T1                                     50                   87                             
   \>T1                                   195                  158                            
  Extrathyroidal invasion                                                            0.207    0.649
   Yes                                    111                  106                            
   No                                     134                  139                            
  Lymph node metastasis                                                              7.401    0.007[a](#tfn3-ijo-53-05-1927){ref-type="table-fn"}
   Yes                                    148                  118                            
   No                                     97                   127                            
  American Joint Cancer Committee stage                                              2.641    0.104
   I+II                                   154                  171                            
   III+IV                                 91                   74                             

P\<0.05. Twelve samples were excluded due to lack of sufficient clinical data. n=490.

[^1]: Contributed equally
